Human bone marrow-derived mesenchymal stem cell-secreted exosomes overexpressing microRNA-34a ameliorate glioblastoma development via down-regulating MYCN. 2019

Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
Department of Neurosurgery, Henan Province People's Hospital, Zhengzhou University, No. 7, Weiwu Road, Zhengzhou, 450003, Henan Province, People's Republic of China.

OBJECTIVE Exosomes play important roles in intercellular communication through signaling pathways affecting tumor microenvironment modulation and tumor proliferation, including those in glioblastoma (GBM). As yet, however, limited studies have been conducted on the inhibitory effect of human bone marrow-derived mesenchymal stem cell (hBMSC)-derived exosomes on GBM development. Therefore, we set out to assess the role of hBMSC secreted exosomes, in particular those carrying microRNA-34a (miR-34a), in the development of GBM. METHODS Microarray-based expression analysis was employed to identify differentially expressed genes and to predict miRNAs regulating MYCN expression. Next, hBMSCs were transfected with a miR-34a mimic or inhibitor after which exosomes were isolated. Proliferation, apoptosis, migration, invasion and temozolomide (TMZ) chemosensitivity of exosome-exposed GBM cells (T-98G, LN229 and A-172) were measured in vitro. The mechanism underlying MYCN regulation was investigated using lentiviral transfections. The in vivo inhibitory effect of exosomal miR-34a was measured in nude mice xenografted with GBM cells through subcutaneous injection of hBMSCs with an upregulated miR34a content. RESULTS We found that poorly-expressed miR-34a specifically targeted and negatively regulated the expression of MYCN in GBM cells. In addition we found that miR-34a was delivered to T-98G, LN229 and A-172 GBM cells via hBMSC-derived exosomes. Exogenous overexpression of miR-34a in hBMSC-derived exosomes resulted in inhibition of GBM cell proliferation, invasion, migration and tumorigenesis in vitro and in vivo, while promoting the chemosensitivity of GBM cells to TMZ by silencing MYCN. CONCLUSIONS From our data we conclude that hBMSC-derived exosomes overexpressing miR-34a may be instrumental for the therapeutic targeting and clinical management of GBM.

UI MeSH Term Description Entries
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071447 N-Myc Proto-Oncogene Protein A basic helix-loop-helix leucine zipper (bHLHZ) transcription factor and proto-oncogene protein that functions in cell growth and proliferation. In mammals, it is highly expressed in the brain during embryogenesis and is essential for brain development; it is not expressed in adult tissues. Amplification or overexpression of N-Myc occurs in at least 20% of tumors and is associated with a poor prognosis in cases of NEUROBLASTOMA; ALVEOLAR RHABDOMYOSARCOMA; SMALL CELL LUNG CARCINOMA; and neuroendocrine prostate cancer. BHLHE37 Protein,Class E Basic Helix-Loop-Helix Protein 37,MYCN Protein,N-Myc Protein,NMYC Protein,Class E Basic Helix Loop Helix Protein 37,N Myc Protein,N Myc Proto Oncogene Protein,Proto-Oncogene Protein, N-Myc

Related Publications

Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
January 2020, International immunopharmacology,
Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
June 2022, Regenerative therapy,
Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
August 2019, Aging,
Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
February 2023, Antioxidants (Basel, Switzerland),
Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
October 2025, Human gene therapy,
Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
August 2019, Molecular and cellular biochemistry,
Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
January 2022, Frontiers in bioscience (Landmark edition),
Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
February 2019, The Journal of thoracic and cardiovascular surgery,
Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
February 2020, Molecular and cellular biochemistry,
Bin Wang, and Zhong-Hua Wu, and Ping-Yang Lou, and Chang Chai, and Shuang-Yin Han, and Jian-Fang Ning, and Ming Li
December 2020, Aging,
Copied contents to your clipboard!